Loading...
NPI 1053314146 · Novi, MI · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Biotech Clinical Laboratories Inc is a clinical medical laboratory provider located in Novi, Michigan. This profile covers 216 Medicare and 235 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Biotech Clinical Laboratories Inc |
| Address | 25775 Meadowbrook Rd |
| City | Novi |
| State | MI |
| ZIP | 48375 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | May 23, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $49.9M |
| Medicare | $8.1M |
BIOTECH CLINICAL LABORATORIES INC is a Clinical Medical Laboratory based in NOVI, MI with an NPI enumerated on 2005-05-23 (~21 years ago), indicating over two decades of active enrollment. The provider’s public claims profile shows sustained, high-volume laboratory operations across both Medicare and Medicaid payers.
The provider’s payer mix is heavily weighted toward Medicaid in scale: reported Medicaid revenue is $49.9M compared with Medicare revenue of $8.1M, indicating the business is effectively Medicaid-dominant by revenue. This imbalance means Medicaid reimbursement and utilization patterns will drive overall financial performance and network leverage more than Medicare.
Revenue concentration is extreme at the code level for both payers: the top 3 Medicare codes account for 45.1% of the provider’s Medicare revenue, while the top 3 Medicaid codes account for 79.8% of the provider’s Medicaid revenue. Those precomputed shares point to heavy dependence on a small set of services for both lines of business, with particularly acute concentration on Medicaid.
The facility’s service-line profile shows a clear specialization in definitive drug testing alongside high-throughput routine clinical testing. Medicaid data show enormous volume for G0482 (159.4K claims, $19M revenue, 41.2% of Medicaid revenue) and G0483 (102.6K claims, $14.7M revenue, 31.9% of Medicaid revenue), and Medicare also reports significant G0482 activity (8.2K claims, $1.6M revenue, 26.0% of Medicare revenue), consistent with functioning as a reference lab focused on multi-class confirmatory drug panels plus standard chemistries.
Competitive standing for definitive drug testing is dominant: on Medicare the provider’s G0482 billing ranks #6 of 1618 providers nationally (100th percentile; extreme outlier), and on Medicaid it ranks #1 of 67 in-state (100th percentile; extreme outlier) with G0483 also ranking #1 of 62 in-state (100th percentile; extreme outlier). These rank/percentile positions indicate the provider is a major, statewide leader in high-complexity drug confirmation testing and is an outlier nationally for at least one confirmatory code.
Beyond drug testing, the lab processes very large volumes of routine clinical assays that support ongoing outpatient testing workflows. Examples on Medicare include 80053 (38.1K claims, $380.6K revenue) and 80061 (28.8K claims, $373.8K revenue) both with 100th-percentile national ranks, and on Medicaid notable volumes include 80053 (101.9K claims, $611.6K revenue) and 84443 (83.5K claims, $751.7K revenue), indicating the operation couples specialized confirmatory testing with high-throughput panel and endocrine testing.
From a contracting and utilization-management perspective, the combination of very high Medicaid scale and extreme code-level concentration (top 3 Medicaid codes = 79.8% of Medicaid revenue) creates both negotiating leverage and a single-service sensitivity: changes to Medicaid coverage, reimbursement, or utilization controls for G0482/G0483/G0480 would materially affect revenue. Payers and network managers should prioritize these definitive drug-test lines when modeling exposure or setting reimbursement policies.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
216 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 8,210 | $190 | $1.6M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3,080 | $240 | $739K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 27,030 | $20 | $432.5K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 13,980 | $30 | $405.4K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 38,060 | $10 | $380.6K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 28,750 | $10 | $373.8K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 39,190 | $10 | $313.5K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 30,680 | $10 | $245.4K |
| 82607 | The lab analyst performs a test to measure the amount of vitamin B12 in a patient specimen, typically in patient blood. | 11,200 | $20 | $168K |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 17,760 | $10 | $159.8K |
Showing 1–10 of 216
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 216 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
216 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0483 | 3 | 20 | 140 | $240 | $206.2K |
| G0482 | 1 | 50 | 140 | $190 | $109.1K |
| G0480 | 3 | 30 | 270 | $110 | $63.5K |
| G0481 | 12 | 40 | 120 | $150 | $62.1K |
| 87481 | 6 | 10 | 130 | $30 | $27.2K |
| 84134 | 3 | 10 | 70 | $10 | $26.3K |
| 88305 | 160 | 470 | 440 | $30 | $23.1K |
| 87637 | 3 | 20 | 80 | $140 | $23K |
| 80307 | 18 | 120 | 130 | $60 | $21.3K |
| 83718 | 5 | 10 | 30 | $10 | $19.7K |
Showing 1–10 of 216
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
235 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 159,420 | $120 | $19M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 102,560 | $140 | $14.7M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 45,590 | $70 | $3.1M |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 26,270 | $40 | $972K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 57,640 | $20 | $864.6K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 19,910 | $40 | $816.3K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 83,520 | $10 | $751.7K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 8,860 | $80 | $690.9K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 87,720 | $10 | $614.1K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 101,930 | $10 | $611.6K |
Showing 1–10 of 235
How this provider's Medicaid billing volume and revenue compare to other Michigan providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Michigan median
235 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 60 | 1,310 | $130 | $1.1M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 70 | 680 | $100 | $604K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 142 | 160 | 2,720 | $60 | $546.6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5 | 50 | 650 | $80 | $298.5K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 37 | 130 | 1,180 | $80 | $231.2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3 | 150 | 2,250 | $30 | $202.4K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 28 | 180 | 2,600 | $20 | $162K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 29 | 190 | 2,610 | $20 | $160.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 24 | 240 | 2,430 | $20 | $152.2K |
| 88307 | The physician, typically a pathologist, performs a level V examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 61 | 80 | 850 | $50 | $149.4K |
Showing 1–10 of 235
Other providers in the same ZIP code as Biotech Clinical Laboratories Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Cns Healthcare | MI | Psychiatry Physician | $0 | $214.3M |
| Theoria Medical | MI | Internal Medicine Physician | $0 | $9.6M |
| University Pediatricians Autism Center | MI | Behavior Analyst | $0 | $9.1M |
| Novi Surgery Center LLC | MI | Ambulatory Surgical Clinic/Center | $1.5M | $0 |
| Eric Kovan | MI | Physical Medicine & Rehabilitation Physician | $510.6K | $0 |
| Dorin Deitch | MI | Physical Medicine & Rehabilitation Physician | $283.1K | $0 |
| Jenny Michaels | MI | Physical Medicine & Rehabilitation Physician | $251K | $0 |
| Jessica Martinelli | MI | Nurse Practitioner | $178.5K | $0 |
| Michael Haenick | MI | Physical Medicine & Rehabilitation Physician | $167.1K | $0 |
| Thomas Sheppard | MI | Physical Therapist | $153.2K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.